Please login to the form below
goserelin acetate
This page shows the latest goserelin acetate news and features for those working in and with pharma, biotech and healthcare.
AZ agrees to $320m deal for Zoladex
ongoing. A further $70m is also up for grabs should Zoladex (goserelin acetate implant) meet a series of sales-related milestones.
Latest news
-
NICE gives partial backing to Ferring's prostate cancer drug
luteinising hormone releasing hormone (LHRH) agonists leuprolide acetate and goserelin.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- LEO Pharma enters clinical trial partnership with ICON
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
